AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04295538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elezanumab
Description: Solution for infusion; Intravenous (IV)
Study NCT04295538 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; Intravenous (IV)
Study NCT00982254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral insulin
Description: oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
Study NCT00982254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular human insulin
Description: subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
Study NCT02077738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFCWO (Hill-Rom Vest™ Airway Clearance System)
Description: study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
Study NCT04417556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sleep measurement
Description: Sleep measurement with polysomnography, actigraphy, and Thai-version Richards Campbell Sleep Questionnaire.
Study NCT00691158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide (Amylin)
Description: 4.7 mls of Amylin 15mcg/ml IV bolus.
Study NCT00691158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: 4.7 mls normal saline IV bolus x1
Study NCT00691158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 Metreleptin
Description: Receive .06mg/kg of metreleptin IV bolus x1
Study NCT00691158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin plus Pramlintide
Description: receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
Study NCT03139175 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: balance assessment with Biodex balance system
Description: All subjects of three groups will be assessed with the evaluation device( balance system).
Study NCT03139175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balance assessment with Biodex balance system
Description: All subjects of three groups will be assessed with the evaluation device( balance system).
Study NCT03139175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balance assessment with Biodex balance system
Description: All subjects of three groups will be assessed with the evaluation device( balance system).
Study NCT01032850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib & Capecitabine
Description: Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
Study NCT03612115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)
Study NCT04448743 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: 20 Ml blood sample
Study NCT03545490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early nutritional intervention
Description: Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
Study NCT03545490 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early nutritional intervention
Description: Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
Study NCT03089346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)
Description: Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
Study NCT03089346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computed tomography (CT)
Description: Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
Study NCT01076920 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: 60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
Study NCT04057508 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Modulation of muscle sympathetic nerve activity
Description: Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
Study NCT04057508 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modulation of muscle sympathetic nerve activity
Description: Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
Study NCT00566111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
Study NCT00566111 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
Study NCT03808831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fall detection and prevention system
Description: The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
Study NCT03808831 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham fall detection and prevention system
Description: The sham system with record but no alert function
Study NCT01868464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG TICE strain
Description: All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.
Study NCT00479323 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax 23
Description: Licensed pneumococcal vaccine (Pneumovax 23).
Study NCT04108871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Biopsy
Description: Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
Study NCT04108871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate Biopsy
Description: Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
Study NCT01811680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable Speed and Sensing Treadmill
Description: open label study on variable speed and sending treadmill training for hemiplegic gait training.
Study NCT03814083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Description: Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
Study NCT03814083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-tDCS
Description: Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
Study NCT03814083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham-tDCS
Description: Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
Study NCT03814083 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
Study NCT03814083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: No intervention
Study NCT03814083 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wait-list
Description: No intervention
Study NCT00810355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group
Description: General support and problem solving for work activity
Study NCT00810355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support Group
Description: General support and problem solving for work activity
Study NCT00810355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
Study NCT00810355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computerized training to enhance cognitive functioning.
Study NCT01479023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-U3-1287
Study NCT01684046 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® MPDS
Study NCT01479023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287 (unlabeled)
Study NCT01313676 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator once daily via novel dry powder inhaler
Study NCT01684046 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RevitaLens MPDS
Study NCT01684046 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Contact Lenses
Description: Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
Study NCT03312114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab\* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
Study NCT01612858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
Study NCT01612858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
Study NCT02838316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)
Description: Autologous muscle derived stem cells
Study NCT01359137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Probation as usual
Description: Routine probation with do deferred jail condition.
Study NCT01359137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deferred Jail
Description: Discretionary deferred jail in response to violations of probation conditions.
Study NCT00397215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)
Description: intramuscular injection
Study NCT00397215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
Study NCT02949531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen
Study NCT01706978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Trephination
Study NCT01706978 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Trephination
Study NCT01669135 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spinal Anesthesia with cerebral oxygen saturation monitoring
Study NCT03515252 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Killer Cells (IKC)
Study NCT00607984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa melphalan
Description: thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
Study NCT04330274 — intervention group
Intervention type: OTHER
Intervention: Bipedal with open eyes
Description: Standing bipedal with open eyes on force platform
Study NCT04330274 — intervention group
Intervention type: OTHER
Intervention: Bipedal with closed eyes
Description: Standing bipedal with closed eyes on force platform
Study NCT04330274 — intervention group
Intervention type: OTHER
Intervention: Bipedal with open eyes and with platform
Description: Standing bipedal with open eyes and with platform under heel of prosthetic foot on force platform
Study NCT04330274 — intervention group
Intervention type: OTHER
Intervention: Bipedal with closed eyes and with platform
Description: Standing bipedal with closed eyes and with platform under heel of prosthetic foot on force platform
Study NCT01359137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arizona's SAFE
Description: Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
Study NCT04444180 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Virtual hand illusion (VHI)
Description: Using VHI, the two basic self-representation of sense of ownership and sense of agency of the subjects will be observed.
Study NCT04433663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis
Description: To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome.
Study NCT04433663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentalization -based therapy using novel tool to demonstrate eating behavior and control axis
Description: To address the gap between theory and practice in the treatment of eating disorders we y developed a novel axis, ECOSA, to better conceptualize the complex interaction between eating style, control conditions, and the impact of the emotional brain versus the thinking brain. A randomized pilot study was used to evaluate the integration of this tool in a mentalization-based treatment compared to treatment as usual (IPT).~Methods: The suggested tool was tested in a randomized blinded feasibility study using the Eating Attitudes Test (EAT-26) and the Reflective Functioning Questionnaire RFQ - as the main outcome.
Study NCT01385280 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic estradiol
Description: Given orally (PO)
Study NCT01385280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO
Study NCT01385280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01385280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies
Study NCT04358861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical Root canal therapy
Description: After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
Study NCT04358861 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical Root canal therapy
Description: After administration of LA and rubber dam isolation, acess cavity was prepared using carbide burs. Working length was determined using root ZX apex locator and was verified radiographically. Canal preparation was done with protaper gold rotary instruments. 5ml of 5.25% NaOCl was used as irrigant. After instrumentation , the canals were irrigated with 5.0 ml of 17% EDTA for 1minute followed by irrigation with 5.0 ml of 5.25% NaOCl. Canals were dried with absorbent paper points, filled with calcium hydroxide paste and access cavity was restored with IRM.At the recall appointment ; after one week,paste removal, copious irrigation was done with 5.25% NaOCl and canals were dried with paper points. Canals were obturated with Gutta-Percha and ZOE based sealer.
Study NCT04358861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental operating microscope
Description: Dental operating microscope; a high magnification and illumination device was used in experimental group for performing nonsurgical root canal therapy.
Study NCT00668174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
Study NCT04487587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cediranib, Olaparib
Description: Cediranib film coated tablet, Olaparib film coated tablet
Study NCT04487587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cediranib, Olaparib
Description: Cediranib film coated tablet, Olaparib film coated tablet
Study NCT00287573 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Express2
Description: Paclitaxel-Eluting Coronary Stent System
Study NCT00287573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy (beta source)
Description: Brachytherapy (beta source)
Study NCT03014102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thrombopoietin
Description: Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
Study NCT03014102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Thrombopoietin
Description: Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
Study NCT02756104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: phenotyping Tcells
Description: Collecting blood for analyses of the T cells phenotypes
Study NCT02756104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supplementation in vitamin D
Description: Supplementation in vitamin D for the patients who are deficient on vitamin D
Study NCT04416139 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion IV of Mesenchymal Stem cells
Description: Mesenchymal Stem cells from bank will be applied IV, at dose 1 million xKg in a single dose
Study NCT02735915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster Vaccine GSK1437173A
Description: Intramuscular injection